Impact ledger
Roche Holding AG (ADR) (RHHBY): the developments shaping its investment case
Follow the evidence affecting Roche Holding AG (ADR). Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research Roche Holding AG (ADR) · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-23 · 2 reports
Roche Reports 15.5% Weight Loss in Phase II Trial for Enicepatide
Channel: Successful advancement of a high-potential drug candidate into Phase III, significantly increasing the probability of future market entry and substantial revenue generation in the lucrative obesity/diabetes market.
Bullish· 1-5y
2026-09-23
Roche to Acquire Ionis Pharmaceuticals, Inc.
Channel: Acquisition cost and potential dilution vs. pipeline enhancement and future revenue growth. Positive clinical trial results for a key pipeline asset.
mixed· 1-3m
2026-09-13 · 3 reports
FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy
Channel: Potential competitive pressure or market expansion in the SMA treatment landscape.
watch· 3-12m
Event impact log
9 events mapped to RHHBY since 2026-09-12. Evidence through 2026-09-23.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-23 | Roche to Acquire Ionis Pharmaceuticals, Inc. | Acquisition cost and potential dilution vs. pipeline enhancement and future revenue growth. Positive clinical trial results for a key pipeline asset. | mixed | 1-3m | 0.60 |
| 2026-09-23 | Roche Reports 15.5% Weight Loss in Phase II Trial for Enicepatide | Successful advancement of a high-potential drug candidate into Phase III, significantly increasing the probability of future market entry and substantial revenue generation in the lucrative obesity/diabetes market. | Bullish | 1-5y | 0.80 |
| 2026-09-23 | Roche Reports 15.5% Weight Loss in Phase II Trial of Dual GLP-1/GIP Agonist Enicepatide | Direct competitive positioning and future revenue potential from a promising pipeline asset in a high-growth therapeutic area. | Bullish | 1-5y | 0.80 |
| 2026-09-13 | FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted SMA Therapy | Increased competition in the Spinal Muscular Atrophy (SMA) market, potentially impacting market share and pricing power for existing therapies. | mixed | 3-12m | 0.30 |
| 2026-09-13 | FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy | Potential competitive pressure or market expansion in the SMA treatment landscape. | watch | 3-12m | 0.30 |
| 2026-09-12 | FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMA | Increased competition in the SMA treatment market, potential for market share shift or pricing pressure. | watch | 3-12m | 0.30 |
| 2026-09-12 | FDA Approves Isembyld for Spinal Muscular Atrophy | Increased competition in the SMA treatment market, potential erosion of market share for existing therapies. | Bearish | 1-3m | 0.50 |
| 2026-09-12 | FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapy | Increased competition in the Spinal Muscular Atrophy (SMA) treatment market. | Bearish | 1-3m | 0.50 |
| 2026-09-12 | FDA approves Scholar Rock's Isembyld for spinal muscular atrophy | Increased competition in the Spinal Muscular Atrophy (SMA) market, potentially impacting market share and pricing power for existing therapies. | mixed | 3-12m | 0.30 |
Continue this research
Build your Roche Holding AG (ADR) investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the RHHBY entity page →